Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Izalontamab brengitecan + Osimertinib in First-Line EGFR-Mutant Advanced NSCLC
NCT07680790Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2026
- Primary completion
- Dec 2031
- Countries
- 16
01
Overview
A Phase 3 trial of izalontamab brengitecan in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Sep 2026; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07680790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07680790.